Drug maker Amgen announced today that it has reached a global settlement with AbbVie, developer of reference adalimumab (Humira), over Amgen’s biosimilar adalimumab, Amgevita.
Drug maker Amgen announced today that it has reached a global settlement with AbbVie, developer of reference adalimumab (Humira), over Amgen’s biosimilar adalimumab, Amgevita.
Under the agreement, AbbVie will grant patent licenses to Amgen for the sale of its drug on a country-by-country basis. As part of the settlement, the companies have dismissed all pending litigation over the drug.
Neither company disclosed the financial terms of the agreement, but Amgen indicated that it will launch its drug, to be marketed as Amgevita, in the European Union on October 16, 2018. In the United States, the biosimilar will be marketed under a slightly different name—Amjevita—and will launch on January 31, 2023.
"We look forward to leveraging our existing biologics capabilities to bring high-quality biosimilars to patients worldwide. [Amgevita] will be one of our first biosimilar launches, and this agreement will allow us to secure a strong foothold in the $4 billion European adalimumab market," said Scott Foraker, vice president and general manager of biosimilars at Amgen.
The FDA approved Amgen’s biosimilar drug in September 2016, and the European Commission authorized its marketing in March 2017. However, litigation over AbbVie’s patents for the innovator Humira had made it unclear when the biosimilar would become commercially available. AbbVie had sued Amgen for infringing on 10 of its patents covering adalimumab.
News of today’s settlement raises questions as to whether a similar agreement could be forthcoming for AbbVie and Boehringer Ingelheim (BI), which saw its own biosimilar adalimumab, Cyltezo, approved by the FDA in August and recommended for approval by the European Medicines Agency’s Committee for Medicinal Products for Human Use earlier this month.
In Cyltezo’s case, AbbVie filed an even more extensive lawsuit against BI, saying that BI would infringe on 74 patents. The first phase of BPCIA litigation over Cyltezo’s alleged infringement will involve 8 of those patents, as BI did not consent to AbbVie’s proposal of a single wave of patent litigation.
The reference Humira is the top selling drug in the world, earning AbbVie $16.08 billion in 2016. While its global sales grew by 14.7% last year, biosimilar competition and the introduction of new drugs are expected to erode its dominance in the rheumatoid arthritis and inflammatory disease marketplace.
FDA and Industry Experts Unpack Biosimilar Device Requirements
October 23rd 2024At the GRx+Biosims 2024 conference, a panel of industry experts and FDA officials discussed evolving device requirements for biosimilars and interchangeable biosimilars, highlighting new approaches to comparative use human factors studies, regulatory challenges, and alternative validation methods.
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
Biosimilars Gastroenterology Roundup for May 2024—Podcast Edition
June 2nd 2024On this episode of Not So Different, we review the biggest gastroenterology biosimilar stories from May 2024, covering new data from conferences and journals on infliximab and adalimumab products that demonstrate positive clinical results and confirm the safety of these biosimilars, as well as the feasibility of switching to them.
Revolutionizing Biopharmaceuticals: The EU's Biosimilar Success and Remaining Challenges
October 16th 2024The European Union's (EU) approach to biosimilars has revolutionized the biopharmaceutical market by driving innovation, lowering costs, and increasing adoption; however, there remains a need for more education, real-world evidence, and efforts to address challenges to enhance patient access and affordability.
Eye on Pharma: Aflibercept Legal Drama; PBM, Humira Biosimilars; Denosumab Regulatory Review
October 15th 2024Regeneron appeals legal decision after judge refuses to block an aflibercept biosimilar; Prime Therapeutics, a pharmacy benefit manager (PBM), becomes the latest to offer biosimilars referencing Humira (adalimumab) at a low cost; the FDA and European Medicines Agency accept a denosumab biosimilar candidate for review.